Research Results in Pharmacology 2(1): 52-57, doi: 10.18413/2313-8971-2016-2-1-52-57
DEVELOPMENT AND VALIDATION OF METHODS OF QUANTITATIVE DETERMINATION OF THE NEW ANTIDIABETIC DRUG IN THE BLOOD PLASMA OF RATS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH MASS SPECTROMETRIC DETECTION
expand article infoAndrey A. Buzov, Alexandr Kulikov, Tatyana Valeryevna Avtina, Mikhail Vladimirovich Pokrovskii, Ol'ga A. Osipova

Corresponding author: Andrey Buzov ( aa_buzov@mail.ru )

© 2018 Andrey Buzov, Alexandr Kulikov, Tatyana Avtina, Mikhail Pokrovskii, Ol'ga Osipova.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation: Buzov A, Kulikov A, Avtina T, Pokrovskii M, Osipova O (2016) DEVELOPMENT AND VALIDATION OF METHODS OF QUANTITATIVE DETERMINATION OF THE NEW ANTIDIABETIC DRUG IN THE BLOOD PLASMA OF RATS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH MASS SPECTROMETRIC DETECTION. Research Results in Pharmacology 2(1): 52-57. https://doi.org/10.18413/2313-8971-2016-2-1-52-57
Open Access
Abstract
We developed a method of quantification of the new antidiabetic drug 3-(1h-benzimidazole-2-yl)-1,2,2-trimethyl-cyclopentane-carbonic acid (c7070) in the blood plasma of rats by high-performance liquid chromatography with mass-spectrometric detection. The analytical range of the method was 0.02-3876.0 μg in 1 ml of blood plasma. The research was partially supported by the grant of the President of the Russian Federation № MD-4711.2015.7 and МК-6135.2016.4.
Keywords
antidiabetic agent, С7070, the blood plasma of rats, high-performance liquid chromatography, mass spectrometric detection, validation